81 related articles for article (PubMed ID: 9675550)
1. In vitro combined effect of a new series of copper (II) complexes with cisplatin or epirubicin on human breast and cervical cancer cell lines.
Geromichalos GD; Katsoulos GA; Hadjikostas CC; Kortsaris AH; Kyriakidis DA
Drugs Exp Clin Res; 1998; 24(2):93-104. PubMed ID: 9675550
[TBL] [Abstract][Full Text] [Related]
2. In vitro synergistic effects of some novel Cu(II) complexes in combination with epirubicin and mitomycin C against HeLa-S3 cervical cancer cell line.
Geromichalos GD; Katsoulos GA; Hadjikostas CC; Kortsaris AH; Kyriakidis DA
Anticancer Drugs; 1996 Jun; 7(4):469-75. PubMed ID: 8826615
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo.
Arandjelovic SS; Bjelogrlic KS; Malesevic NN; Tesic LjZ; Radulovic SS
J BUON; 2009; 14(2):271-9. PubMed ID: 19650178
[TBL] [Abstract][Full Text] [Related]
4. [In vitro combined effects of pirarubicin (THP) and various antitumor drugs on human tumor cell lines].
Nagasawa M; Ishii S; Kariya Y; Itoh O; Yamamoto H; Kawaharajo K; Takeuchi T
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):633-8. PubMed ID: 2108612
[TBL] [Abstract][Full Text] [Related]
5. In vitro antitumor activity of a new platinum complex, DWA2114R against human tumor cell lines.
Akamatsu K; Saito H; Tsunenari T; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1993; 13(6A):2261-5. PubMed ID: 8297143
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anticancer activity of Thiazolo[5,4-b]quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells.
González-Sánchez I; Lira-Rocha A; Navarrete A; Loza-Mejía MA; Coronel-Cruz C; Mendoza-Rodríguez CA; Cerbón MA
Anticancer Res; 2012 Dec; 32(12):5159-65. PubMed ID: 23225412
[TBL] [Abstract][Full Text] [Related]
7. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Kozar K; Kaminski R; Legat M; Kopec M; Nowis D; Skierski JS; Koronkiewicz M; Jakóbisiak M; Golab J
Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
[TBL] [Abstract][Full Text] [Related]
8. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells.
Futagami M; Sato S; Sakamoto T; Yokoyama Y; Saito Y
Gynecol Oncol; 2001 Sep; 82(3):544-9. PubMed ID: 11520153
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative activity of vitamin D compounds in combination with cytostatics.
Pelczynska M; Switalska M; Maciejewska M; Jaroszewicz I; Kutner A; Opolski A
Anticancer Res; 2006; 26(4A):2701-5. PubMed ID: 16886680
[TBL] [Abstract][Full Text] [Related]
10. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
12. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
Wigington DP; Urben CM; Strugnell SA; Knutson JC
Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
14. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
15. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
16. Effects of the Medicago scutellata trypsin inhibitor (MsTI) on cisplatin-induced cytotoxicity in human breast and cervical cancer cells.
Lanza A; Tava A; Catalano M; Ragona L; Singuaroli I; Robustelli della Cuna FS; Robustelli della Cuna G
Anticancer Res; 2004; 24(1):227-33. PubMed ID: 15015601
[TBL] [Abstract][Full Text] [Related]
17. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
[TBL] [Abstract][Full Text] [Related]
19. [Synergistic effect of toremifene and cisplatin on human lung cancer cell line A549].
Zhang X; Li Q; Han Y; Liu Z
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):537-9. PubMed ID: 12667319
[TBL] [Abstract][Full Text] [Related]
20. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
